Longevity & AgingmRNA Flu Vaccine Outperforms Standard Shots in Adults Over 50
A large phase 3 trial found that Moderna's mRNA-based seasonal influenza vaccine, mRNA-1010, was superior to standard-dose licensed flu vaccines in adults aged 50 and older. The trial enrolled over 40,000 participants across multiple countries. Recipients of mRNA-1010 had a 26.6% lower rate of RT-PCR-confirmed influenza-like illness compared to those receiving the standard-dose comparator. The vaccine met all three pre-specified efficacy thresholds: noninferiority, superiority, and higher-level superiority. Side effects were more common with mRNA-1010, including injection-site pain, fatigue, headache, and muscle aches, but were mostly mild to moderate and short-lived. Serious adverse events were rare and comparable between groups.
